Trial Profile
Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Aspirin; Warfarin
- Indications Cerebral infarction
- Focus Therapeutic Use
- Acronyms DECISIVE
- 15 Nov 2021 Primary endpoint of composite of clinical cerebral infarct or new cerebral MRI lesions has not been met, according to results presented at the American Heart Association Scientific Sessions 2021.
- 15 Nov 2021 Results presented at the American Heart Association Scientific Sessions 2021
- 11 Jan 2021 Status changed from active, no longer recruiting to completed.